|Bid||0.00 x 1100|
|Ask||78.25 x 800|
|Day's Range||51.30 - 53.15|
|52 Week Range||47.00 - 136.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.33|
A former Puma Biotechnology Inc (PBYI.O) executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing. Robert Gadimian, 48, was sentenced by U.S. District Judge William Young in Boston after pleading guilty in November to seven counts of securities fraud for carrying out illicit trades that prosecutors said allowed him to earn about $1 million. Prosecutors said that from 2013 to 2014, Gadimian twice secretly traded Puma stock and options based on information he learned about positive developments regarding clinical trials involving neratinib before the company announced the news.
HACKENSACK, N.J., June 18, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials. The first trial, NSABP FB10 is a phase II study evaluating the combination of trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer (NCT02236000) and is currently enrolling patients.
NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amphenol ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2018 American Society of Clinical Oncology Annual Meeting that is currently taking place in Chicago.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m.
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to close at 2,711.45.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / Puma Biotechnology shares sank on Thursday after it revealed concerning information about Nerlynx, a prescription medicine used to treat adults who have early-stage breast cancer, as well as its first quarter earnings. Puma Biotechnology, Inc. shares closed down 20.67% on almost 5.5 million shares traded yesterday.
The Los Angeles-based company said it had a loss of 65 cents per share. Earnings, adjusted for stock option expense, were 2 cents per share. The results surpassed Wall Street expectations. The average ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 16, at the Bank of America Merrill Lynch Health Care Conference 2018. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / U.S. equities were mixed Friday as strong earnings reports from major companies failed to boost investor's enthusiasm. The Dow Jones Industrial Average dropped ...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Wednesday, May 9, 2018 following release of its first quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on the Company's website for 90 days.
Puma Biotechnology, Inc. , a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® in Argentina, Brazil, Chile, Colombia, Mexico and the rest of Latin America.
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced today that NERLYNX® has been included as a recommended treatment option in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Central Nervous System Cancers for Breast Cancer patients with brain metastases.
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
I am going to run you through how I calculated the intrinsic value of Puma Biotechnology Inc (NASDAQ:PBYI) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Litigation:
Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m.